Trial Profile

Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cavrotolimod (Primary) ; Cemiplimab (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Head and neck cancer; Leiomyosarcoma; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Exicure

Most Recent Events

30 Mar 2022 Status changed from active, no longer recruiting to discontinued.
10 Dec 2021 Status changed from recruiting to active, no longer recruiting.
10 Dec 2021 According to an Exicure media release, the company announced Discontinuation of further enrollment and the ethical wind down of the Company's ongoing Phase 1b/2 cavrotolimod (AST-008) clinical trial in patients with solid tumors

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com